Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2015

Dopaminergic, serotonergic, and noradrenergic deficits in
Parkinson disease
Chandana Buddhala
Washington University School of Medicine in St. Louis

Susan K. Loftin
Washington University School of Medicine in St. Louis

Brandon M. Kuley
Washington University School of Medicine in St. Louis

Nigel J. Cairns
Washington University School of Medicine in St. Louis

Meghan C. Campbell
Washington University School of Medicine in St. Louis

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Buddhala, Chandana; Loftin, Susan K.; Kuley, Brandon M.; Cairns, Nigel J.; Campbell, Meghan C.;
Perlmutter, Joel S.; and Kotzbauer, Paul T., ,"Dopaminergic, serotonergic, and noradrenergic deficits in
Parkinson disease." Annals of Clinical and Translational Neurology. 2,. 949-959. (2015).
https://digitalcommons.wustl.edu/open_access_pubs/4350

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

Authors
Chandana Buddhala, Susan K. Loftin, Brandon M. Kuley, Nigel J. Cairns, Meghan C. Campbell, Joel S.
Perlmutter, and Paul T. Kotzbauer

This open access publication is available at Digital Commons@Becker: https://digitalcommons.wustl.edu/
open_access_pubs/4350
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Abstract
Objective: People with Parkinson disease (PD) frequently develop dementia,
which is associated with neocortical deposition of alpha-synuclein (a-syn) in
Lewy bodies and Lewy neurites. In addition, neuronal loss and deposition of
aggregated a-syn also occur in multiple subcortical nuclei that project to neocortical, limbic, and basal ganglia regions. Therefore, we quantified regional
deficits in innervation from these PD-affected subcortical nuclei, by measuring
the neurotransmitters and neurotransmitter transporter proteins originating
from projections of dopaminergic neurons in substantia nigra pars compacta,
serotonergic neurons in dorsal raphe nuclei, noradrenergic neurons in locus
coeruleus, and cholinergic neurons in nucleus basalis of Meynert. Methods:
High-performance liquid chromatography and novel enzyme-linked
immunosorbent assays were performed to quantify dopaminergic, serotonergic,
noradrenergic, and cholinergic innervation in postmortem brain tissue. Eight
brain regions from 15 PD participants (with dementia and Braak stage 6 a-syn
deposition) and six age-matched controls were tested. Results: PD participants
compared to controls had widespread reductions of dopamine transporter in
caudate, amygdala, hippocampus, inferior parietal lobule (IPL), precuneus, and
visual association cortex (VAC) that exceeded loss of dopamine, which was only
significantly reduced in caudate and amygdala. In contrast, PD participants had
comparable deficits of both serotonin and serotonin transporter in caudate,
middle frontal gyrus, IPL, and VAC. PD participants also had significantly
reduced norepinephrine levels for all eight brain regions tested. Vesicular acetylcholine transporter levels were only quantifiable in caudate and hippocampus
and did not differ between PD and control groups. Interpretation: These
results demonstrate widespread deficits in dopaminergic, serotonergic, and
noradrenergic innervation of neocortical, limbic, and basal ganglia regions in
advanced PD with dementia.
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Introduction

Study participants

The defining histopathologic feature of Parkinson disease
(PD) is the accumulation of misfolded alpha-synuclein
(a-syn) protein in Lewy bodies and Lewy neurites.1
Postmortem examinations of PD brains indicate stagedependent deposition of aggregated a-syn and topographical neuronal loss in multiple subcortical nuclei2
including substantia nigra, nucleus basalis of Meynert
(cholinergic),3 locus coeruleus (noradrenergic),4 and
dorsal raphe nuclei (serotonergic).5,6 Neocortical accumulation of a-syn accompanies the development of
dementia that commonly occurs in PD and likely contributes to impaired function of cortical neurons.7–9
However, the affected subcortical nuclei project rostrally
to striatal, limbic, and neocortical regions; and the loss
of innervation from these nuclei may also contribute to
impaired executive, visuospatial, attentional, and memory function in PD.
Cognitive and psychiatric changes in PD are linked in a
variety of ways to alterations in multiple neurotransmitter
systems.10–14 Previous studies have measured levels of
individual neurotransmitters or transporter proteins in a
limited number of regions such as caudate, putamen, and
neocortex.15–17 However, few studies have examined the
degree to which deficits in multiple neurotransmitter systems occur across neocortical and limbic regions.
The aim of the current study was to determine the
extent of regional deficits in dopaminergic, serotonergic,
noradrenergic, and cholinergic innervation in postmortem
tissue from those that had advanced PD and dementia and
neurologically normal controls. We combined measures of
neurotransmitters and corresponding transporter proteins
in basal ganglia, limbic, and neocortical regions. We used
high-performance liquid chromatography (HPLC) to measure neurotransmitter levels and developed novel sandwich
enzyme-linked immunosorbent assays (ELISAs) to measure relevant transporters. The results indicate widespread
loss of dopaminergic, serotonergic, and noradrenergic
innervation in advanced PD.

The cohort included 15 PD participants with dementia and
six healthy age-matched neurologically normal control participants. All PD participants and one control participant
were recruited through the Movement Disorders Center
(MDC), and five control participants were recruited
through the Knight Alzheimer Disease Research Center
(ADRC); both centers are located at Washington University
in Saint Louis. PD participants had a clear response to levodopa (L-DOPA). Postmortem brain tissue was collected
between April 2008 and May 2013. Inclusion criteria for
the study were (1) PD participants who had a clinical diagnosis of idiopathic PD based on the United Kingdom
Parkinson Disease Society Brain Bank diagnostic criteria18
and either Clinical Dementia Rating (CDR global score) ≥1
or a clinical diagnosis of dementia; and (2) control participants with no family history of PD and no dementia
(CDR ≤ 0.5). Exclusion criteria for all participants were (1)
any neurological diagnosis other than PD; (2) psychiatric
disorders other than depression or anxiety; and (3) unwillingness to consent to brain autopsy.

Motor assessments
MDC clinicians evaluated motor symptoms using the
Unified Parkinson Disease Rating Scale motor subscale III
(UPDRS-III). Evaluations were performed on anti-parkinsonian medications.

Dementia ratings
Dementia was rated using the CDR scale by experienced
raters. The CDR included assessment of whether cognitive
dysfunction was sufficiently severe to impair activities of
daily living. PD participants with CDR ≥ 1, in accordance
with criteria for dementia in PD,19 were included in the
study. PD participants were included in the study regardless of the time of onset of cognitive decline or dementia
(as elicited by history) relative to the onset of motor
symptoms.

Materials and Methods
Tissue dissection
Standard protocol approvals and patient
consents
The Human Research Protection Office at Washington University in Saint Louis approved this study.
Written informed consent to perform a brain autopsy
was obtained from all participants. After death, the
immediate next-of-kin were contacted and confirmed
consent for brain removal and retention for research
purposes.
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The protocols to retrieve, dissect, preserve, perform
histology and immunohistochemistry, and diagnose with
established neuropathologic diagnostic criteria are routinely done in the Betty Martz Laboratory of the Knight
ADRC.20 The brain regions were dissected from frozen
1 cm coronal slices and included the body of the caudate
nucleus; gray matter from anterior cingulate gyrus
(ACG), middle frontal gyrus (MFG), inferior parietal lobule (IPL), precuneus, and visual association cortex
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(VAC); hippocampus/entorhinal cortex; and amygdala.21
Detailed procedures of tissue handling and dissection are
described further in Data S1.

Extraction and analysis of
neurotransmitters by HPLC
Neurotransmitters dopamine (DA), serotonin (5HT), and
norepinephrine (NE) were extracted and analyzed by
HPLC with electrochemical detection using a method
modified from Xia et al.22 described in Data S1.

Extraction and analysis of neurotransmitter
transporter proteins by ELISA
The extraction method for transporter proteins was
adapted from previously published methods23 and is
described in Data S1. Capture and detection antibodies
used for dopamine transporter (DAT), serotonin transporter (SERT), and vesicular acetyl choline transporter
(VAChT) sandwich ELISAs were screened from commercially available antibodies (Table S1). DAT recombinant
protein from Novus Biologicals, LLC, Littleton, CO
(H00006531-P01) was used as a standard for DAT ELISA.
SERT and VAChT ELISAs used recombinant SERT and
VAChT that were expressed as his-tag proteins in
HEK293FT cells and purified by Nickel affinity chromatography based on previous methods,24 described in
more detail in Data S1. The sandwich ELISA protocols
were optimized for each neurotransmitter transporter
protein and also are described in detail in Data S1.

Neurotransmitter Deficits in PD with Dementia

Table 1. Demographics
participants1.

and

clinical

Controls

information

of

the

PD with dementia

Demographics
Participants, N
6
15
Age at death, y
84 (70–100) 79 (71–93)
Male/female, N
2/4
12/3
Clinical characteristics of PD participants with dementia
Age at PD diagnosis, y NA
63 (54–82)
Duration of motor
NA
14 (8–27)
impairment, y
UPDRS-III score
NA
44 (35–73.5)
(OFF medications)
LEDD, mg
NA
800 (0–1350)
SSRI medications, N
NA
10/15
Other antidepressant
NA
2/15
medications4, N
AChE inhibitor
NA
8/15
medications5, N
Neuroleptic
NA
14/15
medications6, N

study

P

NA
0.512
0.043
NA
NA
NA
NA
NA
NA
NA
NA

NA, not applicable; UPDRS, Unified Parkinson Disease Rating Scale;
LEDD, levodopa equivalent daily dose; SSRI, selective serotonin reuptake inhibitors; AChE, acetylcholinesterase.
1
Values are medians (range) unless otherwise indicated.
2
Mann–Whitney U test.
3
Chi-square test.
4
Mirtazepine and venlafaxine.
5
Donepezil, rivastigmine, and galantamine.
6
Quetiapine and clozapine.

pathological information for each participant is included
in Table S2.

Statistical analysis
Data were analyzed using GraphPad Prism software, version 4 (Graph Pad Software, Inc., La Jolla, CA) with
details described in Data S1. Due to unequal group sizes
and non-normal distribution of data points, nonparametric Mann–Whitney U tests were applied to compare
groups for HPLC and ELISA data. All tests were two-tailed
and corrected for multiple comparisons with the Holm–
Bonferroni method25 using a significance level of 0.05.

Results
Demographics and clinical information of
participants
Table 1 summarizes the demographics and clinical information of the study participants. Age at death did not
significantly differ between control and PD participants
(Table 1). The male/female ratio was higher in PD
compared to controls (Table 1). Detailed clinical and

Assay performance characteristics for HPLC
and ELISA assays
The HPLC assay lower limits of quantification (LLOQs)
were 0.025 ng/mL for both DA and NE, and 0.10 ng/mL
for 5HT, corresponding to 0.125 ng/g wet wt for DA and
NE, and 0.5 ng/g wet wt for 5HT. The percent coefficients of variation (%CVs) for DA, 5HT, and NE assays
are reported in Table S3.
Specificity of the ELISA antibodies used for the quantification of DAT, SERT, and VAChT were confirmed by
immunoprecipitation (IP) and western blotting (WB)
(Fig. S1). Representative standard curves for each ELISA
are shown in Fig. S2. The ELISA LLOQs for DAT, SERT,
and VAChT were 0.1, 0.016, and 0.3 ng/mL in the ELISA
well, respectively, which corresponded to 3.3, 0.5, and
9.9 ng/mL in the extracts, and 33, 5, and 99 ng/g wet wt
tissue. Since all group comparisons were performed for
an individual brain region within the same plate and no
comparisons were performed between plates, intraplate %
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dramatically lower in PD and similar to other regions in
PD (Table S4). 5HT/SERT ratios were similar across all
regions for controls and PD.

Neurotransmitter and transporter measures
DA and DAT
PD participants had significantly lower DA levels compared to control participants for caudate and amygdala
(Fig. 1, Table 2). DA levels for control and PD participants in MFG, ACG, hippocampus, IPL, precuneus, and
VAC did not significantly differ (Fig. 1). Table 2 lists
levels of DA in PD expressed as a percentage of controls
and their corresponding P values for all brain regions.
PD participants had widespread significant reductions in
DAT levels compared to control participants for caudate,
hippocampus, amygdala, IPL, precuneus, and VAC (Fig. 1,
Table 2). DAT levels in MFG and ACG did not significantly
differ between control and PD participants (Fig. 1, Table 2).
5HT and SERT
PD participants had significantly lower 5HT levels compared to control participants for four of the eight brain
regions tested, which include caudate, MFG, IPL, and
VAC (Fig. 2, Table 2), whereas 5HT levels did not differ
between control and PD participants for ACG, hippocampus, amygdala, and precuneus (Fig. 2, Table 2).
Similar to 5HT, PD participants also had significantly
lower SERT levels compared to control participants for
the same brain regions that include caudate, MFG, IPL,
and VAC (Fig. 2, Table 2), but not for ACG, hippocampus, amygdala, and precuneus.
NE
PD participants had significantly lower NE levels compared to control participants for all eight brain regions
tested, which include caudate, MFG, ACG, hippocampus,
amygdala, IPL, precuneus, and VAC (Fig. 3, Table 2).
VAChT
VAChT levels were below the LLOQ for samples from
MFG, ACG, amygdala, IPL, precuneus, and VAC. VAChT
levels were only quantifiable and did not significantly differ
between PD and control participants for caudate and
hippocampus (Fig. S3).
Neurotransmitter/transporter ratios
DA/DAT ratio was higher in caudate compared to other
brain regions in controls, whereas caudate DA/DAT was
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Relationship between neurochemical
measures, clinical and pathological features
We grouped PD participants (n = 15) according to different pathological subtypes; a-syn only (n = 6); a-syn with
amyloid b (Ab) deposition (Braak amyloid stages B–C)
(n = 7); and a-syn with Ab plus at least moderate neocortical tau deposition (Braak tau stages 5–6) (n = 2).26 Since
the sample size for the a-syn with Ab plus tau group was
too low to allow statistical testing, we compared the a-syn
only and a-syn with Ab deposition groups and did not find
any significant group differences in any of the neurotransmitter or transporter measures. Furthermore, we did not
find any significant correlations between neurochemical
measures and CDR, Mini Mental State Examination
(MMSE), or UPDRS-III scores within PD participants,
when corrected for multiple comparisons.

Discussion
Postmortem analysis of multiple brain regions in advanced
PD with dementia compared to age-matched neurologically
normal controls revealed widespread reductions in neurotransmitter levels of DA, 5HT, and NE, along with reductions in their corresponding transporter proteins, DAT and
SERT. PD participants had reduced dopaminergic innervation in six brain regions as reflected by significantly reduced
DAT levels in caudate, hippocampus, amygdala, IPL, precuneus, and VAC. Reduced DAT levels were accompanied
by reduced DA in only two regions (caudate and amygdala), which likely reflects exogenous L-DOPA administration. PD participants had reduced serotonergic innervation
in four brain regions (caudate, MFG, IPL, and VAC). In
contrast to the dopaminergic system, regional reductions of
5HT matched that of SERT. Finally, PD participants had
marked reductions in noradrenergic innervation, reflected
by reduced NE levels in all brain regions tested including
caudate, MFG, ACG, hippocampus, amygdala, IPL, precuneus, and VAC. In contrast to the reductions in
dopaminergic, serotonergic, and noradrenergic systems, we
did not observe PD-related reductions in VAChT levels,
but we were only able to quantify VAChT in caudate and
hippocampus. The observed deficits in dopaminergic, serotonergic, and noradrenergic innervation of multiple brain
regions provide insights into PD-related brain dysfunction,
particularly in the context of PD with dementia.
Measurements of DAT revealed more widespread
dopaminergic deficits compared to DA. Relative preserva-
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Figure 1. Comparison of DA and DAT levels between control and PD with dementia participants. DA and DAT levels in control and PD with
dementia for caudate (A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F),
precuneus (G), and visual association cortex (H). Statistically significant group differences (P < 0.05) are indicated by an asterisk. DA, dopamine;
DAT, dopamine transporter; PD, Parkinson disease.

tion of DA levels in regions where DAT losses occur likely
reflects exogenous L-DOPA administration that increases
DA concentration in brain regions with residual DOPA

decarboxylase activity yet does not affect DAT on residual
dopaminergic presynaptic terminals. Similarly, exogenous
L-DOPA could lead to higher than normal levels of DA in
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Table 2. Levels of neurotransmitters and transporters in PD with dementia as a percentage of controls in all brain regions.
DA

Caudate
MFG
ACG
Hippocampus
Amygdala
IPL
Precuneus
VAC

DAT

5HT

SERT

NE

%C

P

%C

P

%C

P

%C

P

%C

P

2.5
158
120
106
27.8
140.3
198.3
176

0.001
0.79
0.9
0.46
0.001
0.84
0.41
0.67

17
97.3
115.4
37.5
18.1
35
36.5
41.8

0.003
0.5
0.8
0.002
0.001
0.001
0.001
0.003

31.6
19.7
52.5
67.4
60.5
16.8
68.6
11.8

0.003
0.001
0.011
0.2
0.06
0.001
0.63
0.003

38.5
19
68.3
102.8
74.6
32.13
66.4
9.9

0.007
0.005
0.17
0.97
0.11
0.001
0.213
0.001

7.3
9.65
3.9
27.3
10.92
4.2
17.6
15.8

0.001
0.001
0.002
0.007
0.002
0.001
0.001
0.001

Shaded boxes represent measures that were significantly different between control and PD with dementia at P < 0.05, adjusted for multiple
comparisons performed for each measure. DA, dopamine; DAT, dopamine transporter; 5HT, serotonin; SERT, serotonin transporter; NE,
norepinephrine; C, control; MFG, middle frontal gyrus; ACG, anterior cingulate gyrus; IPL, inferior parietal lobule; VAC, visual association cortex.

some cortical regions that could potentially relate to
drug-induced cognitive side effects.27 The differences in
DA/DAT ratios among different brain regions in controls
likely reflect regional differences in DOPA decarboxylase
and DA storage capacities for intact DAT-containing
presynaptic terminals. Alternatively, nonselective DA
uptake by SERT or NET also could influence DA/DAT
ratios.28 Higher levels of DA synthesis and storage compared to DAT are likely to cause the significantly higher
DA/DAT ratio measured in caudate compared to cortical
regions in controls (caudate, 0.63; cortical regionsmedian,
0.02). The lower caudate DA/DAT ratio (0.08) in PD
patients indicates a relative loss in DA synthesis and storage capacity for the remaining DAT-containing terminals.
In contrast, regional reductions of 5HT matched reductions of SERT in PD and the relative invariance of 5HT/
SERT ratios across regions in both controls and PD suggest
that exogenous drug administration does not influence
these ratios. PD-related degeneration of 5HT neurons
equally affects local 5HT concentration and presynaptic
terminal membranous SERT, a major difference between
the 5HT/SERT system and the DA/DAT system in PD.
Dramatic reductions of NE levels in all brain regions
reflects extensive loss of innervation from locus coeruleus
neurons, which may further contribute to cortical neuron
dysfunction related to local synucleinopathy in advanced
PD. The loss of NE secondary to locus coeruleus lesions
in animal models alters cerebral oxidative metabolism
and blood flow,29 which fits with the observed excessive
oxidative metabolism in mildly affected, never-medicated
PD patients and could indicate uncoupling of oxidative
phosphorylation.30 Altered oxidative metabolism as well
as other consequences of noradrenergic deficits, including
altered neuroinflammatory pathways,31–33 may contribute
to attention, cognitive, or mood dysfunction in PD.
Our observed neurotransmitter and transporter deficits
in caudate agree with a number of previous studies. The
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reduced caudate levels of DAT for PD participants in our
study agree with previously reported reductions in striatal
DAT by autoradiography,34 immunohistochemistry and
WB,35 positron emission tomography (PET),15 and single
photon-emission computed tomography (SPECT) imaging.36 The magnitude of DA and DAT reductions in caudate (2.5% and 17.5% of controls, respectively) is greater
in our study compared to two other studies, which
observed reductions in DA and DAT markers in caudate
ranging from 9% to 30% of controls, and more pronounced reductions (2–3% of controls) in putamen.16,37
The reduced caudate SERT levels in our study agree with
previous measurements of caudate 5HT,38 and with previous measurements of caudate SERT levels by WB analysis,16 PET,39 and SPECT imaging.40 Reduced caudate NE
was observed in one prior study,41 while another study
did not detect changes in caudate NE.37 Our VAChT
measurements are consistent with findings of in vivo PET
imaging in neurologically normal individuals, where the
density of VAChT is higher in the striatum and hippocampus compared to neocortical regions.42,43
A few previous studies reported neurotransmitter
changes in cortical regions although they examined a
smaller number of regions compared to our study. Our
findings confirm the absence of significant DA loss in
frontal and cingulate cortex for PD participants on LDOPA despite reductions of DA in caudate.38 Similar
changes in the levels of 5HT were observed in frontal
cortex, but unlike our study, significant reductions of
5HT were observed in cingulate cortex.38 Interestingly,
the same group also observed widespread deficits in NE
levels in frontal, cingulate, hippocampus, and entorhinal
cortex, although the relative differences between control
and PD was less pronounced than in our study. The significant reductions in NE in frontal cortex observed by
Goldstein et al.41 also agree with our study. Modest discrepancies in findings between our study and these other
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Figure 2. Comparison of 5HT and SERT levels between control and PD with dementia participants. 5HT and SERT levels in control and PD with
dementia for caudate (A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F),
precuneus (G), and visual association cortex (H). Statistically significant group differences (P < 0.05) are indicated by an asterisk. 5HT, serotonin;
SERT, serotonin transporter; PD, Parkinson disease.

studies may be related to differences in disease duration,
severity of disease, cognitive status, drug exposure, or
analysis methods.

Novel aspects of our study include the analysis of a large
number of brain regions, and the simultaneous
measurement of multiple neurotransmitters with their
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Figure 3. Comparison of NE levels between control and PD with dementia participants. NE levels in control and PD with dementia for caudate
(A), middle frontal gyrus (B), anterior cingulate gyrus (C), hippocampus (D), amygdala (E), inferior parietal lobule (F), precuneus (G), and visual
association cortex (H). Group differences were statistically significant for all of the brain regions tested (P < 0.05), as indicated by an asterisk. NE,
norepinephrine; PD, Parkinson disease.

corresponding transporters in a homogenous population of
end-stage PD. Such concurrent measurements have not
been reported previously, with the exception of two studies
that measured only striatal neurotransmitters and transporters for just dopaminergic and serotonergic systems.16,37
Unlike PET44 or SPECT45 imaging radioligands that bind
to multiple members of the neurotransmitter transporter
family, the DAT, SERT, and VAChT ELISAs developed in
this study are highly specific based on the epitopes recognized by the capture and detection antibodies. These measures were further validated using IP and WB. The results
from the novel ELISAs agree with previous findings of
transporter reductions, suggesting consistency and reliability of the developed assays. Moreover, ELISAs offer an
advantage in sensitivity and throughput compared to
immunohistochemical or WB methods.16,35,46,47 Furthermore, the higher sensitivity of the ELISAs enabled quantification of DAT and SERT in multiple cortical regions where
levels are significantly lower than caudate.
This study has several limitations. The modest sample
size and homogeneously severe cognitive impairment precluded analysis of whether the neurotransmitter or transporter differences relate to specific cognitive phenotypes
associated with PD. The number of males and females was
not equal, particularly in the PD group. The higher percentage of males within the PD group reflects to some
extent the higher prevalence of PD in males,48,49 and also
may be explained by sex differences in participation in the
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study or in the death rates among the PD participants. The
widespread and dramatic differences between PD and control participants are unlikely to be explained by differences
in sex ratios between the two groups, but the possibility
exists that sex may have small influences on baseline levels
which only can be excluded with further studies of larger
sample sizes. The small sample sizes (n = 2–3) obtained
when groups were subdivided based on sex prevented
within group or between group comparisons to investigate
this further using nonparametric statistics. Some measurements demonstrate significant dispersion not only in PD
participants, where variability in disease manifestation may
contribute, but also in control participants. In addition to
biologic variability, additional contributing factors specific
to the nature of this study include variability related to
postmortem intervals, dissection of postmortem tissue, and
drug exposure. The lack of an ELISA for quantification of
NET limited our ability to further assess and confirm the
loss of noradrenergic innervation throughout the brain
regions examined. VAChT ELISA was not sufficiently sensitive to measure VAChT levels in cortical regions, and thus
we were not able to determine whether degeneration of
nucleus basalis cholinergic neurons results in altered
cholinergic innervation of these brain regions.
Our results demonstrate widespread deficits in
dopaminergic, serotonergic, and noradrenergic innervation of neocortical, limbic, and basal ganglia regions in
advanced PD with dementia. Our data do not prove
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whether these findings reflect the presence or absence of
dementia. Future enrollment of additional PD participants with mild and no cognitive impairment will enable
further characterization of the range of neurotransmitter
and transporter deficits in PD, and determine whether
levels are correlated with specific cognitive phenotypes.
The novel DAT and SERT ELISAs could be further
extended to other disorders, such as schizophrenia, Tourette’s syndrome, attention deficit hyperactivity disorder,
or depression, where dysregulation of DAT or SERT are
implicated.50–53 Furthermore, combining postmortem
measurements of neurotransmitters and their corresponding transporters with in vivo PET imaging would be helpful to further define specific brain regions and
neurotransmitter systems affected in PD.
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